RESEARCH

Use of the CHA$_2$DS$_2$VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation

Charlotte Atkinson MSc, Jonathan Hinton MRCP, Edmund B Gaisie BMBS, Arthur M Yue DM FRCP, Paul R Roberts MD FRCP, Dhrubo J Rakhit PhD FRCP FACC and Benoy N Shah MD MRCP FESC

Department of Cardiology, University Hospital Southampton, Southampton, UK

Abstract

Transoesophageal echocardiography (TOE) is frequently performed prior to atrial fibrillation (AF) ablation to exclude left atrial appendage (LAA) thrombus. However, patients undergoing AF ablation are usually anticoagulated, thus making the presence of thrombus unlikely in most cases. This study aimed to determine whether the CHA$_2$DS$_2$VASc scoring system can be used to identify patients that do not require TOE prior to AF ablation. In this single-centre retrospective study, local institutional and primary care databases and electronic patient records were searched to identify patients that had undergone TOE prior to AF ablation. Patient demographics, CHA$_2$DS$_2$VASc score, TOE findings and anticoagulation status were collected for analysis. Over a 7-year period (2008–2014), 332 patients (age 57 ± 10 years; 74% male) underwent TOE prior to proposed AF ablation. CHA$_2$DS$_2$VASc scores of 0, 1, 2 and >2 were found in 39, 34, 15 and 12% of patients, respectively. The prevalence of LAA thrombus was 0.6% (2 patients) and these 2 patients had risk scores of 2 and 4. No patients with a score of 0 or 1 had LAA thrombus. Patients that are classed as low risk by the CHA$_2$DS$_2$VASc score do not require a pre-ablation TOE to screen for LAA thrombus provided they are adequately anticoagulated. This would lead to a significant reduction in health care expenditures by reducing unnecessary TOE requests and thereby improve patient experience.

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the Western world and is associated with significant morbidity and mortality (1). The presence of AF portends a significant risk of thromboembolism, which can cause ischaemic stroke. Clinical risk scores such as the CHADS$_2$ and the CHA$_2$DS$_2$VASc score have been validated for the use of thromboembolic risk stratification in patients with non-valvar AF (2). Lip and coworkers (3) showed that the CHA$_2$DS$_2$VASc score was superior to the CHADS$_2$ score at identifying truly low-risk patients – no patients with a CHA$_2$DS$_2$VASc score of 0 suffered thromboembolic events, whereas 1.4% of the patients with a CHADS$_2$ score of 0 did. Accordingly, the CHA$_2$DS$_2$VASc has replaced the CHADS$_2$ score in daily clinical practice when estimating stroke risk.
Patients with symptomatic AF, which is resistant to at least one anti-arrhythmic medication, may be considered for AF ablation. One of the procedural risks of AF ablation is thromboembolic stroke (4) and one potential mechanism for this is dislodgement of thrombus present in the atria by catheters and wires used during the procedure. The thromboembolic risk during an AF ablation procedure is reportedly 0.5–1.5% (5, 6). Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) recommendations for AF ablation (7) state that patients who are in AF at the time of the ablation should undergo a pre-procedural transoesophageal echocardiogram (TOE) despite anticoagulation status. TOE is the gold standard for thrombus screening in the left atrium (LA) and particularly the left atrial appendage (LAA); TOE has a 93–97% sensitivity and 100% specificity for imaging LA/LAA thrombus when compared to surgical findings (8).

Several studies have shown an increased risk of left atrial thrombus with increasing CHADS2 score. A large single-centre study on 1058 patients correlated CHADS-2 scores with LA appendage findings: the investigators found a significantly increased risk of thrombus with high CHADS2 score, no low-risk patients (score of 0) with thrombus, but there were four patients with a score of 1 (intermediate-risk) where thrombus was found (9).

However, there are a paucity of data relating the CHA2DS2VASc score, which is superior to the CHADS2 score (and has replaced it in clinical practice), to LAA appearances on TOE and thus need for pre-ablation imaging. TOE is not performed universally prior to AF ablation procedures; factors that may affect use of TOE include available resources, potential risks of a semi-invasive test and overall low likelihood of thrombus formation in anticoagulated patients. The aim of this study was to determine whether the CHA2DS2VASc score can successfully predict the risk of LA/LAA thrombus as identified by TOE. Our hypothesis was that the CHA2DS2VASc score could be used in the future to obviate the need for TOE prior to AF ablation on selected low-risk patients, thus improving patient experience and also reducing health care costs.

**Methods**

Consecutive patients who underwent TOE in preparation for AF ablation in our institution between 2008 and 2014 were included in this study. Patients were excluded if they did not have a pre-procedural TOE, if TOE images were not available for review or if there were incomplete demographic data to calculate risk scores. Patient demographics, relevant medical history, cardiac medication and TOE data were reviewed using hospital electronic databases retrospectively and CHA2DS2VASc and CHADS2 scores calculated for the time point at which TOE had been performed.

Standard two-dimensional TOE imaging was performed on all patients using commercially available equipment (Philips iE33 ultrasound systems, Eindhoven, Netherlands) and a multi-plane phase array transducer prior to AF ablation. Standard oesophageal intubation, image acquisition and measurements were performed as per European TOE guidelines (10). The LA and LAA were assessed in multiple mid-oesophageal views. Pulsed-wave Doppler imaging was used to measure LAA emptying velocities and colour Doppler imaging used to assess blood flow within the LAA. All TOEs were reviewed and reported by experienced echocardiologists.

The following data were collected from the TOE studies and reports: cardiac rhythm during the study, presence of LA/LAA thrombus and/or spontaneous echo contrast (SEC) in the LA/LAA and LAA emptying velocities. Thrombus was defined as a uniformly echodense intra-cavity mass distinct from the endocardium and pectinate muscle and present in more than one imaging plane; SEC was defined as dynamic ‘smoke-like’ echoes with characteristic swirling motion; and low LAA emptying velocities were less than 40cm/s (11). An abnormal LA/LAA was defined as the presence of one or more of the aforementioned pathologies. The TOE reports were also reviewed for presence of significant mitral valve disease (moderate or severe regurgitation or stenosis) and any impairment of LV systolic function. When thrombus was identified, the ablation was cancelled and the patient treated appropriately as decided by the patient’s cardiologist.

Prior to AF ablation, all patients were anticoagulated with either warfarin or novel oral anticoagulants (NOAC). Patients taking warfarin required a target INR of between 2.0 and 3.0 four weeks prior to ablation. Patients taking NOACs must have been doing so for at least four weeks prior to ablation. All patients included in this study that were taking NOACs stopped their anticoagulation prior to ablation and LMWH was used up until the ablation.

**Statistics**

Data were reported as mean ± s.d., percentage of total population or median and interquartile ranges. To
determine inter-observer variability, twenty TOE studies were selected randomly and retrospectively reviewed independently by two specialist cardiologists who were blinded to the initial report. The TOE studies were assessed for the presence of LA/LAA SEC or thrombus and low LAA emptying velocities. Cohen’s kappa statistic was used to describe agreement.

**Ethics statement**

In accordance with UK guidance from the National Research and Ethics Service (NRES), this study was registered with our NHS Trust as a Service Evaluation for which local institutional approval was sought and obtained.

**Results**

A total of 346 patients underwent TOE prior to proposed AF ablation, of which 14 patients were excluded due to incomplete data, resulting in a total of 332 patients. The mean age was 57±11 years, 73% were male and 68% of patients had paroxysmal AF: full patient demographics are listed in Table 1. The majority (94.6%) of patients were anticoagulated with warfarin with the remainder (5.3%) with NOACs. Most patients were low-risk, as identified by the CHA2DS2-VASc score, which can be seen in Fig. 1; over a third of patients had a score of 0 and almost three quarters patients had a score of <2 (i.e. 0 or 1). No patients had a score ≥6.

Thrombus was found in two patients (0.6%). Both patients were female, had persistent AF and had high-risk CHA2DS2-VASc scores. One patient, aged 63 years, had a score of 2, due to a history hypertension and female gender. The other patient, aged 56 years, had a score of and 4 on account of a previous TIA, history of diabetes and female gender. Neither of these patients had significant mitral valve disease although one patient had mild LV systolic dysfunction and the other had a history of hypertrophic cardiomyopathy. Both patients were anticoagulated with warfarin; however, one of the patients had a sub-therapeutic INR of 1.5 at the time of the TOE. Images of the thrombus found in the LAA can be seen in Fig. 2. In addition to thrombus, as expected, both patients also had SEC and reduced LAA emptying velocities seen on TOE.

Despite only 2 patients having thrombus identified, there were in total 28 patients (8%) that had SEC and 80 (24%) that had reduced LAA emptying velocities. The majority of patients (73%) had a completely normal LA/LAA as assessed by TOE. There were 89 patients that had an abnormal LAA (either SEC and/or reduced LAA emptying velocities) but without evidence of thrombus. Only 19 patients (6%) had a degree of LV systolic dysfunction and 7 (2%) had an abnormal mitral valve. Table 2 demonstrates the abnormal echo findings according to CHA2DS2-VASc score.

There were two patients diagnosed with peri-procedural thromboembolic events during the study period. Both patients were anticoagulated with warfarin and both had therapeutic INR readings in the preceding 4 weeks prior to the ablation procedure. Although both patients had SEC in the LA appendage, neither patient had thrombus on their pre-procedural TOE.

**Inter-observer variability**

To determine the inter-observer variability, 20 patients were selected randomly and the echocardiographic data were re-assessed. Two independent imaging cardiologists

<table>
<thead>
<tr>
<th>Table 1 Baseline patient demographics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
</tr>
<tr>
<td>Age (years; mean ± s.d.)</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Previous stroke/TIA</td>
</tr>
<tr>
<td>History of vascular disease</td>
</tr>
<tr>
<td>CHA2DS2-VASc score (median + IQR)</td>
</tr>
<tr>
<td>CHADS2 score (median + IQR)</td>
</tr>
<tr>
<td>Paroxysmal AF</td>
</tr>
<tr>
<td>Persistent AF</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; IQR, interquartile range; NOAC, novel oral anticoagulant; PAF, paroxysmal atrial fibrillation; s.d., standard deviation; TIA, transient ischaemic attack.
retrospectively reviewed the TOEs in a blinded manner for LA/LAA thrombus, SEC and reduced LAA emptying velocities. The overall agreement for the presence of thrombus was excellent (100%, $k = 1.00$).

**Discussion**

The principal findings of this study are that thrombus prevalence in anticoagulated patients undergoing TOE prior to AF ablation is very low (0.6%) and that no patients with a CHA$_2$DS$_2$VASc score of 0 or 1 had LA/LAA thrombus. All patients with LA/LAA thrombus had a high-risk ($\geq 2$) CHA$_2$DS$_2$VASc score which, therefore, had a 100% sensitivity for prediction of LA/LAA thrombus.

The presence of LA/LAA thrombus is associated with thromboembolic events, particularly stroke and TIA, in patients with AF (12). One of the most significant risks associated with AF ablation is that of thromboembolism. This study has demonstrated a very low prevalence (0.6%) of LA/LAA thrombus in patients undergoing AF ablation. These results are consistent with other studies with similar cohorts of patients (mean age 57–60 years, majority (64–80%) male, all undergoing TOE prior to AF ablation, with similar anticoagulation protocols) who also found thrombus prevalence to be between 0.5% and 2.3% (9, 13, 14).

There have been studies that have found much higher thrombus prevalence; however, in these studies, the patient cohort and anticoagulation protocols were different. For example, a study by Yarmohammadi and coworkers (15) found a thrombus prevalence of 11.8% in a study of 541 patients awaiting cardioversion, but these patients had no anticoagulation at all. Similarly, a further study by Yarmohammadi and coworkers (16) identified a thrombus prevalence of 6% in a group of 2369 patients undergoing cardioversion who had been anticoagulated with warfarin but many had a sub-therapeutic INR. In this current study, all patients received oral anticoagulation for at least 4 weeks prior to TOE, with a target INR of between 2.0 and 3.0. These differences in thrombus prevalence, despite differences in patient cohorts, highlight the importance of appropriate anticoagulation when considering LA/LAA thrombus.

Nevertheless, from this study and others, it is evident that despite therapeutic anticoagulation, there is still a slim chance of thrombus formation in certain AF patients. One patient in this study with LA/LAA thrombus had a
Table 2  Table of abnormalities by CHA₂DS₂VASc score.

<table>
<thead>
<tr>
<th>CHA₂DS₂VASc score</th>
<th>n</th>
<th>Thrombus</th>
<th>Spontaneous echo contrast (%)</th>
<th>Reduced LAA velocity (&lt;40cm/s) (%)</th>
<th>LV systolic dysfunction (%)</th>
<th>Abnormal MV structure/ function (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>128</td>
<td>0</td>
<td>8</td>
<td>24</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>113</td>
<td>0</td>
<td>4</td>
<td>19</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>50</td>
<td>1</td>
<td>12</td>
<td>38</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>27</td>
<td>0</td>
<td>7</td>
<td>22</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>1</td>
<td>33</td>
<td>25</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

LAA, left atrial appendage; LV, left ventricle; MV, mitral valve.

Sub-therapeutic INR (1.5) at the time of TOE. However, the other patient had a therapeutic INR of 3.1 and LA/LAA thrombus was still present. Puwanant and coworkers (9) demonstrated similar findings in their study of 1058 patients where 6/8 patients with LA/LAA thrombus had a sub-therapeutic INR, whilst the other two patients with thrombus had INRs of 2.5. These data demonstrate that therapeutic anticoagulation with warfarin, although important, does not eliminate the risk of thrombus formation in patients with AF.

Although most patients were anticoagulated with warfarin, 5.3% (17 patients) were taking NOACs. The safety and efficacy of NOACs and their use prior to AF ablation is well established (17, 18, 19) and guidelines currently recommend at least three weeks of NOAC therapy prior to ablation (20). None of the patients in this study taking a NOAC had LA/LAA thrombus; their demographics were comparable to the rest of the population, and the CHA₂DS₂VASc scores ranged from 0 to 5, similar to the population on warfarin. This finding is consistent with other studies that have shown that the incidence of thrombus in patients undergoing pre-ablation TOE is either similar (21) or less (22) than those patients on warfarin.

In addition to anticoagulation, most patients in this cohort were classed as either low (39%) or intermediate-risk (34%) with a CHA₂DS₂VASc score of 0 or 1, respectively. This is consistent with data from studies by Scherr and coworkers (23), Puwanant and coworkers (9), and Herring and coworkers (14) who all found that nearly half of their patients (50, 47 and 42.5% for each study, respectively) undergoing TOE prior to AF ablation had a CHADS₂ score of 0.

In our study, both patients with LA/LAA thrombus had persistent AF. There is no clear consensus on whether type of AF (i.e. paroxysmal vs. persistent) can be used to determine need for TOE. The 2007 HRS Task Force (7) suggested that TOE should always be performed in patients with persistent AF despite anticoagulation status, whereas patients with PAF and in sinus rhythm during the ablation would not require a TOE. However, the results from the large study by Puwanant and coworkers (9) identified two patients with LA/LAA thrombus or sludge who had PAF and were in sinus rhythm at the time of the TOE. These results highlight that simply using the clinical history of AF and the rhythm at the time of the ablation is not sufficient to exclude the risk of LA/LAA thrombus. Unfortunately, due to conflicting results in recently published studies (14, 23, 24, 25), the updated HRS guidelines (26) were not able to offer further evidence-based clarification on these guidelines.

The current study has demonstrated that there were no patients with a CHA₂DS₂VASc score of 0 or 1 with LA/LAA thrombus; this agrees with several other studies (14, 27, 28) as listed in Table 3. A study by Nishikiti-Tachibana looked at 541 Japanese patients undergoing TOE before AF ablation and demonstrated that there were no patients with a CHA₂DS₂VASc score of 0 with LA thrombus; however, there were four patients (2.8%) with a CHA₂DS₂VASc score of 1 with LA/LAA thrombus, despite therapeutic oral anticoagulation with warfarin (29). Interestingly, this study found a relatively high thrombus prevalence of 6.4%, which they attribute to a higher proportion of patients with persistent AF than other studies; however, it is relatively similar to those reported in this study (38% and 32%, respectively). It is more likely that their population had a larger proportion of high-risk patients (58% have CHA₂DS₂VASc score ≥2, compared to this study with 28%), due to differences in local AF ablation guidelines.

Clinical implications and recommendations

There are currently no clear guidelines on which patients require a TOE prior to AF ablation. The 2007 HRS/EHRA/ECAS (7) guidelines for AF ablation recommend that TOE may not be required in patients with PAF in sinus rhythm at the time of the procedure. Subsequent HRS AF guidelines
produced in 2012 (26) reported conflicting opinions on this matter and provided no clear recommendations. More recently, the EHRA have suggested that the CHA₂DS₂VASc score may be useful in determining which patients require a TOE, particularly when the score is ≥2 (20), which this study supports.

From the current study, taking into consideration the guidance documents and all other studies available, we suggest that all (anticoagulated) patients with a CHA₂DS₂VASc score of 0 or 1 do not require a TOE prior to AF ablation, provided they are therapeutically anticoagulated for at least 4 weeks with either warfarin (with a stable INR of between 2.0 and 3.0) or a NOAC, regardless of cardiac rhythm. If this guidance were followed, it would significantly reduce the need for TOE (73% or 241 patients over a 7-year period in our study) and would not have missed a single patient with thrombus. Indeed, since these results were presented to our local electrophysiologists, we have amended our institution’s policy and, with an initial desire to be ‘cautious’ rather than ‘cavalier’, we no longer perform TOE routinely in patients with a CHA₂DS₂VASc score of 0 awaiting AF ablation: this has led to a 35% reduction in TOE requests in the first 6 months following the introduction of this policy.

To the best of our knowledge, there have been no patients in any of the published studies with a CHA₂DS₂VASc score of 0 where LA/LAA thrombus has been identified. These results are summarised in Table 3. This reduction in TOE would provide significant cost savings for the health service and, in addition, the reduction in TOEs would improve patient experience markedly, because although low risk, TOEs can be an unpleasant experience for patients.

### Study limitations

This was an observational, retrospective, single-centre study. All data were collected retrospectively using patient records and therefore subject to potential misclassification. The patient cohort consisted of mostly low-risk patients with few co-morbidities (only 26% had a CHA₂DS₂VASc ≥2, 12% had a history of stroke/TIA, and 1% had CHF) and thus may not be generalisable to other populations.

### Table 3 Summary of studies that have examined LA/LAA thrombus in patients undergoing TOE prior to AF ablation and their CHA₂DS₂VASc scores.

<table>
<thead>
<tr>
<th>Authors</th>
<th>n</th>
<th>Scoring system</th>
<th>Mean age ± s.d. (years)</th>
<th>Proportion of patients with score of 0</th>
<th>Thrombus prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Floria et al. (27)</td>
<td>681</td>
<td>CHADS₂ and CHA₂DS₂VASc</td>
<td>57.0 ± 11.0</td>
<td>Not available</td>
<td>7 patients (1.0%)</td>
</tr>
<tr>
<td>Willens et al. (28)</td>
<td>167</td>
<td>CHADS₂ and CHA₂DS₂VASc</td>
<td>66.3 ± 11.6</td>
<td>CHADS₂: 16 (9.6%)</td>
<td>5 patients (3.0%)</td>
</tr>
<tr>
<td>Herring et al. (14)</td>
<td>586</td>
<td>CHA₂DS₂VASc</td>
<td>59.9 ± 0.4</td>
<td>CHADS₂: 249 (42.5%) CHA₂DS₂VASc: 11 (6.6%)</td>
<td>3 patients (0.5%)</td>
</tr>
<tr>
<td>Nishikii-Tachibana et al. (29)</td>
<td>543</td>
<td>CHADS₂ and CHA₂DS₂VASc</td>
<td>61.9 ± 9.9</td>
<td>CHADS₂: 161 (29.7%) CHA₂DS₂VASc: 84 (15.5%)</td>
<td>35 patients (6.4%)</td>
</tr>
</tbody>
</table>

Thrombus scores

- CHADS₂: 14% with thrombus had a score of 1, 86% with thrombus had a score ≥2
- CHA₂DS₂VASc: 100% with thrombus had a score ≥2
Importantly, there were very few patients with LA/LAA thrombus identified, likely due to the anticoagulation protocols and low-risk patient cohort. Finally, the number of patients anticoagulated with NOACs in the study was small. As the use of NOAC agents continues to increase, further larger studies on patients anticoagulated with NOACs will be required.

**Conclusion**

Patients with a CHA_{2}DS_{2}VASc score of zero or one (a significant proportion of patients awaiting AF ablation) can safely undergo ablation without the need for pre-procedural TOE. This would lead to a significant reduction in health care expenditures, reduce burden of clinical waiting lists and improve patient experience by removing requirement for a semi-invasive test in these patients.

---

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

---

**Funding**

This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

---

**References**


9. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WHW, Gabriel RS, Wazni OM, Bhargava M, Saliba WJ, Thomas JD, et al. 2009 Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing left atrial appendage thrombus identification, likely due to the anticoagulation of patients anticoagulated with NOACs in the study was small. As the use of NOAC agents continues to increase, further larger studies on patients anticoagulated with NOACs will be required.

**Conclusion**

Patients with a CHA_{2}DS_{2}VASc score of zero or one (a significant proportion of patients awaiting AF ablation) can safely undergo ablation without the need for pre-procedural TOE. This would lead to a significant reduction in health care expenditures, reduce burden of clinical waiting lists and improve patient experience by removing requirement for a semi-invasive test in these patients.

---

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

---

**Funding**

This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

---

**References**


Received in final form 25 July 2017
Accepted 17 August 2017
Accepted Preprint published online 21 August 2017